Target Audience
Specialists or physicians in training in infectious diseases, clinical microbiology and other disciplines dealing with the prudent use of antibiotics, clinical pharmacology, drug development, regulatory issues and health-care policies.

Conference Objectives
This conference presents and summarizes currently available knowledge regarding the clinical use of some off-patent antibiotics and will discuss gaps of knowledge and future areas of research as well as how breakpoints may have to be reviewed, how dosing and administration of the agents may have to change, guidelines revised, and what the implications for regulatory issues may be. The key ambition is to explore ways to better preserve the efficacy of these agents in an era of escalating multi-drug resistance.

Organizing Committee
David Hooper, Boston, MA, United States
William Hope, Liverpool, United Kingdom
Gunnar Kahlmeter, Växjö, Sweden
Ursula Theuretzbacher, Vienna, Austria

Programme Committee
David Andes, Madison, WI, United States
Marco Cavaleri, London, United Kingdom
Ed Cox, Silver Spring, MD, United States
George Drusano, Lake Nona, FL, United States
William Hope, Liverpool, United Kingdom
Gunnar Kahlmeter, Växjö, Sweden
Jason Roberts, Brisbane, Australia
Keith Rodvold, Chicago, IL, United States
Ursula Theuretzbacher, Vienna, Austria
Programme Overview

Starting date/time
21 September, 12:00

End date/time
23 September, 16:15

Plenary Sessions
- ESCMID introductory lecture. Mario Poljak, ESCMID President
- AMR: a global challenge. TBD
- Drug discovery within the context of AMR: extending beyond ‘me too’ drugs. Tom Parr
- Drug development within the context of AMR: giving new molecules the best chance. John Rex

Symposia
New chemical space: where are new antibiotics coming from?
Chair: Tom Parr
- Antibiotics do not necessarily obey Lopinsky rules. Matt Cooper
- Discovering new antibiotics in nature. Heike Brötz-Osterhelt
- Why target-based drug discovery has not been very successful. David Payne
- Getting drugs into Gram-negative bacteria. Mathias Winterhalter

Techniques for accelerating and de-risking drug development
Chair: William Hope
- Utilizing PK/PD to increase the probability of successful drug development. Paul Ambrose
- Strength and limitations of pre-clinical models for drug development. Sujata Bhavnani
- Developments in PK/PD modelling and approaches: what to do when the standard model does not describe the data. Elisabet Nielsen
- PK/PD to decrease the development of drug resistance in new molecules. Arnold Louie

In-vitro susceptibility testing and establishing breakpoints for new compounds
Chair: Alasdair MacGowan
- Current tools and approaches for setting breakpoints. Johan Mouton
- Global harmonization of breakpoints – can it be achieved? Gunnar Kahlmeter
- Regulatory issues around test development and validation. Ron Jones
- What is a wild-type population and how is it defined? TBD

Innovative clinical trial design for AMR
Chair: Stephan Harbarth
- Real world challenges in performing clinical trials for drug resistant disease. Steve Projan
- Developing drugs in combination. Michael Dudley
- Debate: PK/PD versus frequentist approaches for drug development – Pro. Tom Lodise
- Debate: PK/PD versus frequentist approaches for drug development – Con. Dean Follmann

Developing new drugs for AMR in special populations
Chair: Mike Sharland
- Pharmacometrics for special populations. Johannes Van den Anker
- Challenges in developing drugs for critical illness. Jean Chastre
- Addressing therapeutic challenges of AMR in neonates. John Bradley
- Approaches for defining safe and effective regimens for children. Michael Sharland

Recent advances in regulation to meet the challenge of AMR
Chair: Christa Wirthumer-Hoche
- FDA. Ed Cox
- EMA. Marco Cavalieri
- Common regulatory issues for drug development programmes. Mair Powell

Getting AMR research funded
Chair: Keith Rodvold
- Overview of the current efforts. Herman Goossen
- From big pharma to small and back again. TBD

Interactive Session
- Round table: resources for antibiotic drug discovery. Moderator: David Hooper
  - MRC. Jonathan Pearce
  - BARDA. Joe Larsen
  - NIH. Dennis Dixon

Conclusion and closing of the conference
- Open planning meeting for the 2017 conference in the United States

Organization

Conference Registration
The online registration form is available on www.escmid.org/Vienna2016.

Registration Fees
- ESCMID/ASM Members
  - Before and on 22 July 2016: EUR 600
  - After 22 July 2016: EUR 800
- All others
  - Before and on 22 July 2016: EUR 700
  - After 22 July 2016: EUR 900

ESCMID Attendance Grants
ESCMID provides a number of attendance grants for ESCMID “Young Scientist Members”. The grant covers the registration fee, but not travel or accommodation costs. Please submit your application before 13 July 2016 online on the conference website. Applicants will be informed about their acceptance until 20 July 2016.